Demographic and health-related predictors of proton pump inhibitor (PPI) use and association with chronic kidney disease (CKD) stage in NHANES population

Devraj, Radhika; Deshpande, Maithili

doi:10.1016/j.sapharm.2019.08.032

Cited by 11 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Statins and PPIs are common medications in age groups where RCC is most common, in other words, in those aged 40-45 years and older [20][21][22][23]. Furthermore, prescriptions for statins and PPIs increase with advancing age [21,22,24]. Therefore, the use of statins and PPIs may need to be taken into account before initiating sunitinib treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Kidney cancer primarily occurs in those aged ≥45 years [20] and statins are used by approximately 25% of people in the general population aged ≥40 years, with prescription increasing with age [21,22]. Moreover, PPIs are used by approximately 17% of people in the general population aged 60-79 years [23], with approximately 80% of PPI users aged ≥50 years [24].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Effect of Comorbidities/Comedications on Sunitinib Outcomes for Metastatic Renal Cell Carcinoma: the STAR-TOR Registry

et al. 2020

View full text Add to dashboard Cite

Aim: Examine the effects of baseline hypertension (HTN) and statin or proton pump inhibitor (PPI) use on sunitinib treatment outcomes in STAR-TOR, a real-world registry. Materials & methods: Presence or absence of HTN and use or nonuse of statins or PPIs were determined at registry entry. End points included overall survival (OS) and progression-free survival (PFS). Results: Data were from 557 patients. Presence or absence of HTN did not affect OS or PFS. PFS (median [95% CI]) was longer in statin users (9.4 [6.5–13.6] months) versus nonusers (6.9 [5.7–8.2] months) (p = 0.0442). OS was shorter in PPI users (20.2 [14.9–28.3] months) versus nonusers (25.7 [22.7–33.0] months) (p = 0.0212). Conclusion: Comorbidities and comedications may affect real-world sunitinib treatment outcomes. ClinicalTrials.gov identifier: NCT00700258

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Effect of Comorbidities/Comedications on Sunitinib Outcomes for Metastatic Renal Cell Carcinoma: the STAR-TOR Registry

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Given the role of magnesium in the glucose metabolism, various lines of evidence suggest that magnesium can be beneficial for improving insulin resistance and slowing the progression of diabetes-related complications ( 27 ). Proton pump inhibitors can interfere with passive and active magnesium absorption, and several systematic reviews have confirmed hypomagnesemia among individuals using these medications ( 28 ); close to 9% of American adults routinely use these medications ( 29 ).…”

Section: Nutrients Of Concern In Women Across the Life Coursementioning

confidence: 99%

Sex Differences Across the Life Course: A Focus On Unique Nutritional and Health Considerations among Women

Bailey

Dog

Smith‐Ryan

et al. 2022

The Journal of Nutrition

View full text Add to dashboard Cite

In the United States, women, while having a longer life expectancy, experience a differential risk for chronic diseases and have unique nutritional needs based on physiological and hormonal changes across the lifespan. However, much of what is known about health is based on research conducted in men. Additional complexity in assessing nutritional needs within gender include the variation in genetics, body composition, hormonal milieu, underlying chronic disease, and medication usage, with this list expanding as we consider these variables across the life course. It is clear women experience nutrient shortfalls during key periods of their lives, which may differentially impact their health. Consequently, as we move in to the era of precision nutrition, understanding these sex- and gender-based differences may help optimize recommendations and interventions chosen to support health and weight management. Recently, a scientific conference was convened with content experts to explore these topics from a life-course perspective at biological, physiological, and behavioral levels. This publication summarizes the presentations and discussions from the workshop and provides an overview of important nutrition and related lifestyle considerations across the life course. The landscape of addressing female specific nutritional needs continues to grow; now more than ever, it is essential to increase our understanding of the physiological differences between men and women, and how these physiological considerations may aid in optimizing nutritional strategies to support certain personal goals related to health, quality of life, sleep, and exercise performance among women.

show abstract

“…Thus, 17 full-text articles were screened, and 7 studies were further excluded due to being reviews, not a comparison of interest, and having ineligible study designs. Finally, 10 studies were included in this meta-analysis [ 15 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ].…”

Section: Resultsmentioning

confidence: 99%

“… Association between PPI use and risk of chronic kidney disease [ 15 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ]. …”

Section: Figurementioning

confidence: 99%

Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies

Liao

Kung

et al. 2023

JCM

View full text Add to dashboard Cite

Previous epidemiological studies have raised the concern that the use of proton pump inhibitors (PPIs) is associated with an increased risk of kidney diseases. To date, no comprehensive meta-analysis has been conducted to assess the association between PPIs and the risk of chronic kidney disease (CKD). Therefore, we conducted a systematic review and meta-analysis to address the association between PPIs and CKD. The primary search was conducted in the most popular databases, such as PubMed, Scopus, and Web of Science. All observational studies evaluated the risk of CKD among PPI users, and non-users were considered for inclusion. Two reviewers conducted data extraction and assessed the risk of bias. Random-effect models were used to calculate pooled effect sizes. A total of 6,829,905 participants from 10 observational studies were included. Compared with non-PPI use, PPI use was significantly associated with an increased risk of CKD (RR 1.72, 95% CI: 1.02–2.87, p = 0.03). This updated meta-analysis showed that PPI was significantly associated with an increased risk of CKD. Association was observed in the same among moderate-quality studies. Until further randomized control trials (RCTs) and biological studies confirm these results, PPI therapy should not stop patients with gastroesophageal reflux disease (GERD). However, caution should be used when prescribing to patients with high-risk kidney disease.

show abstract

Demographic and health-related predictors of proton pump inhibitor (PPI) use and association with chronic kidney disease (CKD) stage in NHANES population

Cited by 11 publications

References 27 publications

Effect of Comorbidities/Comedications on Sunitinib Outcomes for Metastatic Renal Cell Carcinoma: the STAR-TOR Registry

Effect of Comorbidities/Comedications on Sunitinib Outcomes for Metastatic Renal Cell Carcinoma: the STAR-TOR Registry

Sex Differences Across the Life Course: A Focus On Unique Nutritional and Health Considerations among Women

Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies

Contact Info

Product

Resources

About